Medial EarlySign, an Israel-based health IT startup, released an evaluation Feb. 5 of its predictive model that identifies diabetic patients at high risk for kidney damage.
Here are three things to know about the company's findings.
1. Medial EarlySign's machine learning model analyzes patient information from EHRs — such as demographics, medication and laboratory tests — to predict patients at high risk for having renal dysfunction within one year.
2. Following an analysis of 400,000 diabetes patients' data, the model identified 45 percent of the patients who went on to experience renal dysfunction within a year. The model identified 25 percent more patients compared to those identified with commonly used clinical tools, according to Medial EarlySign.
3. Medial EarlySign's goal for the model is facilitate early identification and treatment of renal dysfunction, which may successfully prevent or slow the progression of kidney damage.
"Medial EarlySign's algorithm can aid decision-makers, drug developers, insurers and providers to better allocate their capped resources and secure preferential clinical outcome," said Ran Goshen, MD, PhD, CMO of Medial EarlySign.